Arvinas Says ARV-102 Shows Dose-Dependent Eye Movement Improvement In 24-Patient Phase 1 Parkinson's Trial Not Designed To Assess Efficacy
Share
Why It Matters
Arvinas tested a Parkinson's medicine on 24 people. Early signs showed it helped eye movement more at higher doses, but the trial was too small to prove it works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.